Jump to any asset
849 assets, updated daily
Pfizer vs Merck & Co.
VS
Comparative Analysis
Merck (MRK) wins this head-to-head comparison against Pfizer (PFE), primarily driven by its superior profitability and stronger revenue growth. While both companies operate in the pharmaceutical sector, MRK demonstrates a stronger financial profile. Its higher return on equity and assets, coupled with better revenue growth, suggest a more efficient and expanding business. PFE, despite a higher dividend yield, lags behind MRK in key profitability and growth metrics. MRK's ability to consistently beat earnings estimates, even on a negative EPS basis, indicates operational resilience and market confidence. Technically, both stocks show mixed signals, but MRK's stronger fundamentals provide a more compelling case for investment at this juncture. The valuation gap, while present, is justified by MRK's superior performance.
Key Differentiator
Merck's (MRK) superior profitability, evidenced by its significantly higher return on equity and assets, is the key differentiator against Pfizer (PFE). This enhanced capital efficiency, combined with stronger revenue growth and a more positive analyst sentiment, positions MRK as the more compelling investment despite its higher valuation. MRK's ability to consistently beat earnings expectations further solidifies its operational strength.
Joint Outlook
Merck (MRK) is expected to continue its upward trajectory, driven by its strong profitability and ongoing revenue growth, with analysts projecting a median target of $152.50. Pfizer (PFE) faces a more uncertain outlook, with its current price near the median analyst target and mixed fundamental indicators suggesting slower appreciation. In a bullish scenario, MRK could see further upside if its pipeline delivers blockbusters, while PFE might benefit from a broader market rally or successful cost-containment measures. Conversely, a bearish scenario for MRK would involve pipeline setbacks or increased competition, while PFE could face pressure if its revenue growth falters or if broader market sentiment turns negative.
Price Analysis Comparison
Valuation Metrics
| Metric | PFE | MRK |
|---|---|---|
| P/E Ratio | 36.60 | 119.02 |
| Market Cap | 163.41B | 367.07B |
| Price/Sales | 2.52 | 5.51 |
| Price/Book | 1.89 | 8.76 |
| EV/EBITDA | 8.38 | 14.34 |
| Dividend Yield | 6.00% | 2.29% |
Merck (MRK) trades at a significantly higher P/E ratio of 119.02 compared to Pfizer (PFE) at 36.60, indicating a premium valuation for MRK. However, MRK's price is closer to its 52-week high ($148.78 vs $156.92 high) than PFE ($28.67 vs $29.21 high), suggesting stronger recent price momentum for MRK. PFE's 52-week range is narrower ($23.58 to $29.21) compared to MRK's ($77.58 to $156.92), implying greater historical volatility for MRK. Despite the higher P/E, MRK's market capitalization is substantially larger ($367B vs $163B), reflecting its greater scale and market presence.
Profitability & Efficiency
| Metric | PFE | MRK |
|---|---|---|
| Rev. Growth (Qtly) | 2.60% | 5.10% |
| Profit Margin | 6.80% | 4.77% |
| Return on Equity | 5.01% | 6.96% |
| Return on Assets | 5.78% | 11.87% |
| Debt/Equity | 74.25 | 128.41 |
MRK also demonstrates significantly better capital efficiency with a return on assets of 11.87%, substantially higher than PFE's 5.78%. While PFE has a slightly higher net profit margin at 6.8%, MRK's stronger returns on equity and assets suggest more effective utilization of its capital base to generate profits.
Earnings Reality Check
PFE
Earnings data unavailable. No recent report data found.
MRK
Last 4 Qs: MRK beat estimates 4x out of 4. Rose 4x after beats.
Technical Indicators
| Indicator | PFE | MRK |
|---|---|---|
| RSI (14) | 54.70 | 46.08 |
| 50-Day MA | $26.98 | $140.38 |
| 200-Day MA | $26.34 | $121.67 |
Merck (MRK) is currently trading at $148.78, below its 20-day EMA ($146.96) but above its 50-day ($140.38) and 200-day ($121.67) SMAs, indicating a mixed but generally positive trend. Pfizer (PFE) is trading at $28.67, above its 20-day EMA ($27.91), 50-day ($26.98), and 200-day ($26.34) SMAs, suggesting a more consistent uptrend. MRK's RSI is 46.08, indicating neutral momentum, while PFE's RSI is 54.7, suggesting slightly more positive momentum. MRK's MACD of 1.90 is positive and above its signal line, indicating bullish momentum, whereas PFE's MACD of 0.28 is also positive but less pronounced.
AI Analyst Sentiment
Technical rating: based on current price action versus moving averages and momentum. This measures short-term chart trend, not analyst opinion or company fundamentals.
PFE
Technical Score: 58/100
MRK
Technical Score: 72/100
Merck (MRK) garners a more favorable analyst rating consensus, with 5 'Strong Buy' and 15 'Buy' ratings out of 28 analysts, and a median target price of $152.50, suggesting potential upside from its current price. Pfizer (PFE) has a more mixed analyst outlook, with 2 'Strong Buy' and 8 'Buy' ratings, but also 16 'Hold' and 1 'Sell' rating among 28 analysts, and a median target price of $28.00, which is very close to its current trading price. The higher concentration of buy-side recommendations and a more optimistic price target for MRK suggest stronger positive sentiment from the analyst community.
Risk Stratification
| Metric | PFE | MRK |
|---|---|---|
| Beta (Volatility) | 0.30 | 0.23 |
| Sharpe Ratio | -0.14 | 0.27 |
For Merck (MRK), the primary risks include its high P/E ratio, which could lead to significant downside if growth expectations are not met, and potential regulatory hurdles or clinical trial failures for its drug pipeline. Pfizer (PFE) faces risks related to its slower revenue growth and lower profitability metrics, which could hinder its ability to compete effectively in the long term. Its mixed analyst ratings also point to uncertainty about its future performance. Both companies are subject to broader pharmaceutical industry risks, including patent expirations, pricing pressures, and evolving healthcare policies. MRK's higher valuation makes it more susceptible to market sentiment shifts, while PFE's fundamental weaknesses present a more persistent operational challenge.
Comparative ProTips
- Consider MRK for its stronger fundamental performance and growth potential, accepting the higher valuation.
- PFE's higher dividend yield may appeal to income-focused investors, but its fundamental metrics suggest caution.
- Monitor MRK's drug pipeline developments closely, as they are critical to sustaining its premium valuation.
Monte Carlo Projection (10yr)
Actionable Trade Plans
Compare entry, exit, and risk management levels for both assets
Select Your Trade Bias
Risk Tolerance
Conservative
3%
Aggressive
Portfolio Value
$
✎
Position Size: $200 - $300 per asset
PFE
Current: $28.67
ENTRY ZONES
Conservative
$27.24
Aggressive
$28.67
RISK MANAGEMENT
STOP LOSS
$26.42
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$28.60
+10%
$29.96
+15%
$31.32
MRK
Current: $148.78
ENTRY ZONES
Conservative
$141.34
Aggressive
$148.78
RISK MANAGEMENT
STOP LOSS
$137.10
MAX LOSS
-3%
Volatility-Adjusted Stop Loss
Calculated based on volatility and technical support levels.
Profit Targets (Based on Conservative)
+5%
$148.41
+10%
$155.48
+15%
$162.54
Calculate Your Trade
Disclaimer
This comparison involves assets with varying risk profiles. The content is for educational purposes only. Identifying the stronger asset is based on relative strength (RS) and technical convergence. Past correlation does not guarantee future lockstep movement. Trading involves risk of loss. Note: The AI favored MRK based on growth trajectory. This is valid for the specified timeframe only.
Frequently Asked Questions
Which is a better buy, MRK or PFE?+
Merck (MRK) is the preferred buy due to its superior profitability, stronger revenue growth, and more positive analyst sentiment, despite a higher valuation. Pfizer (PFE) lags in key financial metrics.
What are the key risks for MRK vs PFE?+
MRK faces risks from its high valuation and pipeline execution, while PFE's risks include slower growth and operational challenges. Both are exposed to industry-wide regulatory and pricing pressures.
How do MRK and PFE compare on profitability?+
Merck (MRK) is more profitable, showing a higher return on equity (6.96% vs 5.01%) and return on assets (11.87% vs 5.78%) compared to Pfizer (PFE).
What is the dividend yield for MRK and PFE?+
Pfizer (PFE) offers a higher dividend yield of approximately 6.00%, while Merck (MRK) provides a yield of about 2.29%.
How do their P/E ratios compare?+
Pfizer (PFE) has a P/E ratio of 36.60, significantly lower than Merck's (MRK) P/E ratio of 119.02.
What is the analyst sentiment for each stock?+
Analysts favor Merck (MRK) more, with a higher proportion of 'Buy' ratings and a more optimistic median target price compared to Pfizer (PFE), which has a more mixed analyst outlook.
How has their recent earnings performance been?+
Merck (MRK) has consistently beaten earnings estimates, whereas Pfizer (PFE) has 'N/A' for recent earnings data, making direct comparison difficult.